Business Wire | Jan 6, 2022 08:35AM EST

Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference

Jan. 06, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 06, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually.

Conference details can be found below:

* J.P. Morgan Healthcare Conference 2022 Format: Corporate presentation and 1-on-1 meetings Date and Time: Presentation at 7:30am ET January 13, 2022 Presentation Link

The presentation and archived webcast can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company"), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022. MARIO-3 is the first eganelisib combination study in frontline advanced cancer patients and is evaluating eganelisib in combination with Tecentriq(r) and Abraxane(r) in frontline TNBC and in combination with Tecentriq and Avastin(r) in frontline RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo(r) (nivolumab) in I/O nave urothelial cancer. MARIO-P is a platform study to evaluate eganelisib to support the initiation of future registration focused studies across various solid tumor indications, which the Company expects to initiate on a rolling basis in 3Q 2022. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo(r) is a registered trademark of Bristol Myers Squibb. Tecentriq(r) is a registered trademark of Genentech, Inc. Abraxane(r) is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company. Avastin(r) is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005362/en/

CONTACT: Investor Relations: Irina Koffler LifeSci Advisors, LLC 646-970-4681 ikoffler@lifesciadvisors.com